WASHINGTON -- The Food and Drug Administration has allowed drugs for cancer and other diseases to stay on the market even when follow-up studies showed they didn't extend patients' lives, say congressional investigators. A report from the Government Accountability Office also shows that the FDA has never pulled a drug off the market due to a lack of required follow-up about its actual benefits - even when such information is more than a decade overdue.
Read article in the Washington Post (USA)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment